Kimberly Blackwell, M.D.
Zentalis Pharmaceuticals, Inc.
Kimberly Blackwell, M.D., is the CEO of Zentalis Pharmaceuticals, Inc., a biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Dr. Blackwells leadership is marked by her commitment to advancing oncology research, driving clinical development, and addressing unmet medical needs in cancer care. With extensive experience in oncology and drug development, she has played a key role in guiding Zentalis Pharmaceuticals through critical stages of research and clinical trials. Her strategic vision focuses on leveraging cutting-edge science to develop novel therapies and improve patient outcomes. Under her guidance, Zentalis Pharmaceuticals is making significant progress in the development of transformative cancer treatments, contributing to advancements in oncology and patient care.